ZEST Trial Offers Insights for Using ctDNA to Predict Breast Cancer Recurrence
The study was terminated early due to low detection of ctDNA after treatment among patients with stage 1 to...
Search/Filter
Loading...
HR-positive, HER2-negative Breast Cancer Patients With High Risk of Recurrence May Benefit From Addition of Anthracyclines to Taxane- based Chemotherapy
Genomic testing helped identify which patients with node-negative, HR-positive, HER2- negative breast cancer could benefit from the addition of...
Multimodal Machine Learning Model Effective at Predicting Response to CDK4/6 Inhibitors in HR-positive, HER2-negative Breast Cancer Patients
Combining real-world clinical and genomic data resulted in a more accurate prediction of outcomes compared to examining clinical and...
Most Patients With Intermediate-risk Breast Cancer May Safely Avoid Chest Wall Irradiation After Mastectomy
SAN ANTONIO – Patients with intermediate-risk breast cancer had similar rates of 10-year overall survival whether or not they...
COMET Trial Finds Active Monitoring Is a Viable Option for Some Patients With Low-risk DCIS
Recurrence risk was similar between active monitoring and usual care groups SAN ANTONIO – Among patients with hormone receptor...
COMET Trial Finds Quality of Life Similar Among Patients with Low- risk DCIS Whether They Received Active Monitoring or Surgery
SAN ANTONIO – Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring reported comparable physical, emotional,...
Adjuvant Tamoxifen May Reduce Recurrence Risk for Patients with ‘Good-risk’ DCIS Who Forgo Radiation
SAN ANTONIO – For patients with “good-risk” ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery and did not...
Next-generation SERD Protects Against Progression in Some Patients With Advanced Breast Cancer Resistant to Standard Hormone Therapy
Imlunestrant was effective in combination with abemaciclib, and as monotherapy in ESR1-mutated breast cancer SAN ANTONIO – Imlunestrant, an investigational...
BRCA-mutation Carriers With a History of Early-onset Breast Cancer May Benefit From Risk-reducing Surgery
SAN ANTONIO – Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40...
PARP Inhibition Shows Long-term Survival Benefits for Patients With High-risk, BRCA-positive Breast Cancer in OlympiA Trial
SAN ANTONIO – Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have...